The Investment Column: Bespak investors can breathe easy
The figures also show that he is capable of moving Bespak beyond the recovery phase to generate real growth, even if the 43 per cent jump in pre-tax profits to pounds 5.03m on turnover up just a tenth to pounds 39.4m reflected the benefits of some one-off factors.
The demise of the US patent over the ageing albuterol asthma treatment (better known as Glaxo Wellcome's Ventolin) led to the launch last January of three generic versions, all of which business Bespak won. Filling three new marketing pipelines, on top of those of existing customers Glaxo and Schering Plough, helped valve sales soar by 28 per cent to around pounds 15.4m in the half-year.
Meanwhile, sales continued to build around Glaxo's Acuhaler, the second- generation dry powder inhaler launched in Scandinavia in 1995.
Bespak's turnover in that product alone more than doubled from under pounds 2m to pounds 4.5m in the six months as the drugs giant rolled the product out across Europe.
Mr Chambre says about half the first-half profits growth came from higher volumes inflated by these developments and concedes that growth will slow from here on. Even so, Bespak can look forward to cashing in on the continuing 6 per cent growth in the US asthma inhaler market and has plenty else to look forward to.
The two-year restructuring of Tenax is nearly complete. The business should be back in profit in the second half, aided by the delayed launch of a new product. There should also be further benefits from sprucing up Bespak's manufacturing efficiency, which, with better customer service and lower costs, is said to have delivered the other half of the first- half profits rise.
Bespak's chances of picking up the manufacturing for the Acuhaler's US launch in 1998 have been improved by Glaxo's decision to raise its maximum order with the group from 10 million to 15 million units a year.
Its credibility is also enhanced by the announcement that Roger Mann, finance director at Siebe, is joining the board.
The only clouds are the switch to non-CFC propellants in inhalers, which could disrupt the market up to 2000, and the half-year collapse in profits in the relatively small personal care division. But even on a prospective p/e ratio of 18, assuming full-year profits of pounds 11m, the shares should have further to go.
- 1 'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
- 2 Number of global billionaires has doubled since the financial crisis
- 3 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
- 4 Of course, teenage girls need role models – but not like beauty vlogger Zoella
- 5 North Korean officials 'publicly executed for watching South Korean soap operas'
'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
Canadian actor punched in face after 'Islamophobia' experiment goes wrong in wake of Ottawa shooting
Number of global billionaires has doubled since the financial crisis
Elizabeth Norment dead: House of Cards actress honoured by Kevin Spacey after she dies aged 61
Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
Pope Francis declares evolution and Big Bang theory are real and God is not 'a magician with a magic wand'
Huge surge in Ukip support after EU funding row, according to new poll
Ukip ‘exploiting grooming scandal’ to secure party’s first police chief
Nigel Farage: 'There’s nothing wrong with white people blacking up'
Muslims, immigration and teenage pregnancy: British people are ignorant about almost everything
Nigel Farage and Frankie Boyle clash over Andrew Lawrence's 'Mock the Week' criticism
iJobs Money & Business
£20000 - £23250 Per Annum pro rata: Clearwater People Solutions Ltd: Pro rata ...
£40 - 48k + Benefits: Guru Careers: We are seeking a Marketing Manager to join...
£45,000 - £65,000: Saxton Leigh: Our client is a well-known APAC Corporate and...
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...